Mutation of the androgen receptor causes oncogenic transformation of the prostate
- PMID: 15657128
- PMCID: PMC544619
- DOI: 10.1073/pnas.0408925102
Mutation of the androgen receptor causes oncogenic transformation of the prostate
Abstract
Recent evidence demonstrates that the androgen receptor (AR) continues to influence prostate cancer growth despite medical therapies that reduce circulating androgen ligands to castrate levels and/or block ligand binding. Whereas the mutation, amplification, overexpression of AR, or cross-talk between AR and other growth factor pathways may explain the failure of androgen ablation therapies in some cases, there is little evidence supporting a causal role between AR and prostate cancer. In this study, we functionally and directly address the role whereby AR contributes to spontaneous cancer progression by generating transgenic mice expressing (i) AR-WT to recapitulate increased AR levels and ligand sensitivity, (ii) AR-T857A to represent a promiscuous AR ligand response, and (iii) AR-E231G to model altered AR function. Whereas transgenes encoding either AR-WT or AR-T857A did not cause prostate cancer when expressed at equivalent levels, expression of AR-E231G, which carries a mutation in the most highly conserved signature motif of the NH2-terminal domain that also influences interactions with cellular coregulators, caused rapid development of prostatic intraepithelial neoplasia that progressed to invasive and metastatic disease in 100% of mice examined. Taken together, our data now demonstrate the oncogenic potential of steroid receptors and implicate altered AR function and receptor coregulator interaction as critical determinants of prostate cancer initiation, invasion, and metastasis.
Figures
![Fig. 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/544619/bin/zpq0050570960001.gif)
![Fig. 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/544619/bin/zpq0050570960002.gif)
![Fig. 3.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/544619/bin/zpq0050570960003.gif)
![Fig. 4.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/544619/bin/zpq0050570960004.gif)
Similar articles
-
A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease.Int J Cancer. 2012 Aug 1;131(3):662-72. doi: 10.1002/ijc.26414. Epub 2012 Jan 24. Int J Cancer. 2012. PMID: 22275114
-
Pleiotropic functional properties of androgen receptor mutants in prostate cancer.Hum Mutat. 2009 Feb;30(2):145-57. doi: 10.1002/humu.20848. Hum Mutat. 2009. PMID: 18800375 Review.
-
Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells.Cancer Res. 2007 Oct 15;67(20):10067-77. doi: 10.1158/0008-5472.CAN-07-1267. Cancer Res. 2007. PMID: 17942941
-
Androgen receptor (AR) coregulators: an overview.Endocr Rev. 2002 Apr;23(2):175-200. doi: 10.1210/edrv.23.2.0460. Endocr Rev. 2002. PMID: 11943742 Review.
-
Collocation of androgen receptor gene mutations in prostate cancer.Clin Cancer Res. 2001 May;7(5):1273-81. Clin Cancer Res. 2001. PMID: 11350894
Cited by
-
Pre-Clinical Models to Study Human Prostate Cancer.Cancers (Basel). 2023 Aug 22;15(17):4212. doi: 10.3390/cancers15174212. Cancers (Basel). 2023. PMID: 37686488 Free PMC article. Review.
-
Cellular specificity of androgen receptor, coregulators, and pioneer factors in prostate cancer.Endocr Oncol. 2022 Sep 8;2(1):R112-R131. doi: 10.1530/EO-22-0065. eCollection 2022 Jan. Endocr Oncol. 2022. PMID: 37435460 Free PMC article. Review.
-
Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance.Cancer Lett. 2021 Oct 10;518:1-9. doi: 10.1016/j.canlet.2021.06.006. Epub 2021 Jun 10. Cancer Lett. 2021. PMID: 34118355 Free PMC article. Review.
-
Decoding the heterogeneous landscape in the development prostate cancer.Oncol Lett. 2021 May;21(5):376. doi: 10.3892/ol.2021.12637. Epub 2021 Mar 15. Oncol Lett. 2021. PMID: 33777200 Free PMC article. Review.
-
Development and prevalence of castration-resistant prostate cancer subtypes.Neoplasia. 2020 Nov;22(11):566-575. doi: 10.1016/j.neo.2020.09.002. Epub 2020 Sep 25. Neoplasia. 2020. PMID: 32980775 Free PMC article. Review.
References
-
- Huggins, C., Stephens, R. C. & Hodges, C. V. (1941) Arch. Surg. 43, 209.
-
- Gingrich, J. R., Barrios, R. J., Morton, R. A., Boyce, B. F., DeMayo, F. J., Finegold, M. J., Angelopoulou, R., Rosen, J. M. & Greenberg, N. M. (1996) Cancer Res. 56, 4096–4102. - PubMed
-
- Tilley, W. D., Buchanan, G., Hickey, T. E. & Bentel, J. M. (1996) Clin. Cancer Res. 2, 277–285. - PubMed
-
- Han, G., Foster, B. A., Mistry, S., Buchanan, G., Harris, J. M., Tilley, W. D. & Greenberg, N. M. (2001) J. Biol. Chem. 276, 11204–11213. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials